The rational design of allosteric kinase modulators is challenging but rewarding. The protein kinase PDK1, which lies at the center of the growth-factor signaling pathway, possesses an allosteric regulatory site previously validated both in vitro and in cells.ANCHOR.QUERYsoftware was used to discover ap otent allosteric PDK1 kinase modulator.U sing ar ecently published PDK1 compound as at emplate,s everal new scaffolds that bind to the allosteric target site were generated and one example was validated. The inhibitor can be synthesized in one step by multicomponent reaction (MCR) chemistry when using the ANCHOR.QUERYapproach.O ur results are significant because the outlined approach allows rapid and efficient scaffold hopping from knownm olecules into new easily accessible and biologically active ones.B ased on increasing interest in allosteric-site drug discovery,w e foresee many potential applications for this approach.Compounds with an allosteric mode of action enable modulation of the protein function that cannot be accomplished by active-site inhibitors. [1] Additionally,a llosteric receptor sites are often less conserved than active sites in ap rotein family.H ence,m ore selective receptor modulation is possible and often new therapeutic qualities can be accomplished. Fore xample,m ost ATP-competitive kinase inhibitors show limited selectivity,a nd therefore clean and selective regulation of acellular pathway is often prohibited. While nonselective kinase inhibitors were considered advantageous for targeting more than one signaling pathway in cancer, some clinical kinase inhibitors show considerable toxicity owing to polypharmacology.M ore-selective kinase inhibitors are potentially better suited for combination with other selective targeted drugs in future personalized treatments.Asasubgroup of the human kinome,the AGCkinases provide au nique opportunity to discover allosteric modulators since ar egulatory allosteric site,t he so called PIFpocket, is well established. [2] Amongst these kinases,3phosphoinositide-dependent protein kinase-1 (PDK1